Research Topics
| Kevin A AultSummaryAffiliation: Emory University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Adenocarcinoma in situ and associated human papillomavirus type distribution observed in two clinical trials of a quadrivalent human papillomavirus vaccineKevin A Ault
Department of Gynecology and Obstetrics and the Emory Vaccine Center, Atlanta, GA 30303, USA
Int J Cancer 128:1344-53. 2011..In summary, our findings show that AIS evades colposcopic and cervical cytologic detection. As most AIS lesions were HPV16/18-related, prophylactic HPV vaccination should reduce the incidence of invasive adenocarcinoma...- Human papillomavirus vaccines: an update for gynecologistsKevin A Ault
Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, Georgia, USA
Clin Obstet Gynecol 51:527-32. 2008..This review will discuss the natural history and epidemiology of HPV, the diseases associated with these infections and current clinical usage of this vaccine. Future developments in this area will also be discussed... 
New antibiotics and vaccines in obstetric practice. ForewordKevin A Ault
Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, Georgia, USA
Clin Obstet Gynecol 51:485. 2008- Long-term efficacy of human papillomavirus vaccinationKevin A Ault
Division of Gynecologic Oncology, Department of Gynecology and Obstetrics, Emory University School of Medicine, 69 Jesse Hill Drive, Atlanta, GA 30064, USA
Gynecol Oncol 107:S27-30. 2007..Population-based long-term efficacy trials conducted in these countries aim to investigate the long-term efficacy of HPV vaccination with regard to invasive cervical cancer, and the results of these trials are awaited with interest... - Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trialsKevin A Ault
Department of Gynecology and Obstetrics, Emory University School of Medicine, 69 Jesse Hill Jr Drive, SE, Atlanta, GA 30303, USA
Lancet 369:1861-8. 2007..In this combined analysis of four clinical trials we assessed the effect of prophylactic HPV vaccination on these diseases... - Programmatic and research priorities for improving influenza immunization of pregnant womenKevin A Ault
Department of Gynecology and Obstetrics and Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA
Am J Obstet Gynecol 207:S75-7. 2012..The 2009 influenza pandemic was accompanied by increased maternal vaccination rates. In this article, we review programmatic and research priorities with regard to overcoming barriers to influenza immunization of pregnant women... - Human papillomavirus vaccines and the potential for cross-protection between related HPV typesKevin A Ault
Division of Gynecologic Oncology, Department of Gynecology and Obstetrics, Emory University School of Medicine, 69 Jesse Hill Jr Drive, S E Atlanta, Georgia 30303, USA
Gynecol Oncol 107:S31-3. 2007..Over a period of 6 months, cross-protection was observed against persistent infections with HPV-45, -31 and -52, and at 12 months, modest protection was demonstrated against persistent infections with 12 combined oncogenic HPV types... 
Epidemiology and natural history of human papillomavirus infections in the female genital tractKevin A Ault
Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, GA 30303, USA
Infect Dis Obstet Gynecol 2006:40470. 2006..New prophylactic HPV vaccines promise to dramatically reduce the incidence of HPV infection, genital warts, and cytologic abnormalities...- Vaccines for the prevention of human papillomavirus and associated gynecologic diseases: a reviewKevin A Ault
Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, Georgia, USA
Obstet Gynecol Surv 61:S26-31. 2006.... - A controlled trial of a human papillomavirus type 16 vaccineLaura A Koutsky
Department of Epidemiology, University of Washington, Seattle, USA
N Engl J Med 347:1645-51. 2002..Although most infections are benign, some progress to anogenital cancer. A vaccine that reduces the incidence of HPV-16 infection may provide important public health benefits... - Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18Luisa L Villa
Department of Virology, Ludwig Institute for Cancer Research, R Prof Antonio Prudente 109, 4th Floor, 01509 010 Sao Paulo, SP, Brazil
Vaccine 24:5571-83. 2006..Following an initial, similar sized decline, anti-HPV responses plateaued and remained stable through end-of-study (3.0 years). No vaccine-related serious adverse experiences were reported... - Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trialConstance Mao
Department of Obstetrics and Gynecology and Epidemiology, University of Washington, Seattle, Washington 98104 2499, USA
Obstet Gynecol 107:18-27. 2006..Whether protection lasts longer than 18 months and, thus, impacts rates of cervical intraepithelial neoplasia (CIN) 2-3 has not yet been established. We present results from an HPV16 L1 VLP vaccine trial through 48 months... - Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trialLuisa L Villa
Department of Virology, Ludwig Institute for Cancer Research, Sao Paulo, Brazil
Lancet Oncol 6:271-8. 2005.... - A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccineKevin A Ault
Department of Obstetrics and Gynecology, University of Iowa Hospitals and Clinics, 200 Hawkins Drive, Iowa City, IA 52242, USA
Vaccine 22:3004-7. 2004..Peak anti-HPV18 geometric mean titers (GMT) in vaccines were 60-fold greater than those observed in women following natural HPV18 infection. Further studies of a multivalent HPV L1 VLP vaccines are warranted... - Does rubella immunity predict measles immunity? A serosurvey of pregnant womenColleen M Kennedy
Department of Obstetrics and Gynecology, Roy J and Lucille A Carver College of Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USA
Infect Dis Obstet Gynecol 2006:13890. 2006..This study was undertaken to determine whether rubella immunity infers measles immunity in pregnant women... - Gynecologists' attitudes regarding human papilloma virus vaccination: a survey of Fellows of the American College of Obstetricians and GynecologistsJanice C Raley
Department of Obstetrics and Gynecology, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USA
Infect Dis Obstet Gynecol 12:127-33. 2004..CONCLUSION: Professional society recommendation is important for acceptability of a potential HPV vaccine. Gynecologists are willing to include this vaccine in their office practice... - Human papillomavirus infections: diagnosis, treatment, and hope for a vaccineKevin A Ault
Department of Obstetrics and Gynecology, University of Iowa Hospitals and Clinics, 200 Hawkins Drive, Iowa City, IA 52242, USA
Obstet Gynecol Clin North Am 30:809-17. 2003..Gynecologists should be familiar with these therapies and their potential short-comings. A recently reported clinical trial has raised hopes that HPV and its sequelae may be prevented by vaccination... - Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccineChristophe Fraser
Imperial College London, London, UK
Vaccine 25:4324-33. 2007....